Author: Tango Therapeutics Sub, Inc

Posted Date:

May 8, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Sub, Inc

May 8, 2026
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Sub, Inc

May 6, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Sub, Inc

May 1, 2026
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Tango Therapeutics Sub, Inc

May 1, 2026
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

Tango Therapeutics Sub, Inc

February 18, 2026
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Tango Therapeutics Sub, Inc

February 3, 2026